摘要
目的观察知柏地黄丸联合坤泰胶囊治疗卵巢储备功能低下患者的临床疗效及安全性。方法将66例卵巢早衰的患者随机分为试验组34例和对照组32例。2组均给予激素人工周期治疗,对照组给予口服坤泰胶囊,每次4粒,tid;试验组在对照组的基础上口服知柏地黄丸,每次8粒,tid。2组均治疗3个月。对比2组治疗后的临床疗效,治疗前、后平均卵巢直径(MOD)、卵巢平均容积(OAV)、窦卵泡数(AFC)、卵巢功能指标、中医证候积分及血清内卵泡刺激素(FSH)、黄体生成素(LH)和雌二醇(E2)水平,观察患者治疗期间药物不良反应发生情况。结果治疗后,试验组和对照组的总有效率分别为94.12%(32例/34例)和71.88%(23例/32例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的MOD分别为(25.42±4.28)和(20.29±3.25)mm;OAV分别为(6.60±1.17)和(5.06±1.36)cm^(3);AFC分别为(5.79±0.88)和(3.97±0.90)个;Kupperman评分分别为(8.82±1.53)和(19.75±5.45)分;中医证候积分分别为(6.94±0.92)和(11.22±1.48)分;FSH分别为(25.50±1.91)和(32.83±3.62)mU·mL^(-1);LH分别为(16.30±3.18)和(26.61±2.95)mU·mL^(-1);E2分别为(65.07±3.20)和(45.42±6.80)pg·mL^(-1)。上述指标,试验组与对照组比较,差异均有统计学意义(均P<0.05)。试验组和对照组患者治疗期间药物不良反应发生率分别为11.76%(4例/34例)和9.38%(3例/32例),差异无统计学意义(P>0.05)。结论知柏地黄丸联合坤泰胶囊治疗卵巢储备功能低下患者具有较好的临床疗效,同时能够促使卵巢功能恢复,改善激素水平,可以提高生活质量,且安全性高。
Objective To observe the clinical efficacy and safety of Zhibai Dihuang Pill combined with Kuntai Capsule in the treatment patients of low ovarian reserve.Methods A total of 66 patients with premature ovarian failure were randomly divided into the treatment group with 34 cases and the control group with 32 cases.Both groups were given hormone artificial cycle therapy.The control group was given Kuntai capsules orally,4 capsules each time,tid;on the basis of control group,the treatment group was given Zhibai Dihuang Pills,8 capsules each time,tid.Both groups were treated for 3 months.The clinical efficacy of the two groups after treatment was compared,the mean ovarian diameter(MOD),the mean ovarian volume(OAV),the number of antral follicles(AFC),ovarian function indexes,traditional Chinese medicine(TCM)syndrome scores and serum follicle stimulating hormone(FSH),luteinizing hormone(LH),estradiol(E2)levels before and after treatment were compared,and monitor the occurrence of adverse reactions during treatment.Results After treatment,the total effective rates of the treatment group and the control group were 94.12%(32 cases/34 cases)and 71.88%(23cases/32 cases),and the difference was statistically significant(P<0.05).After treatment,the MOD of the treatment group and the control group were(25.42±4.28)and(20.29±3.25)mm,respectively;the OAV were(6.60±1.17)and(5.06±1.36)cm^(3),respectively;the AFC were 5.79±0.88 and 3.97±0.90,respectively;the Kupperman scores were 8.82±1.53 and 19.75±5.45,respectively;the TCM syndrome scores were 6.94±0.92 and11.22±1.48,respectively;the FSH were(25.50±1.91)and(32.83±3.62)m U·mL^(-1),respectively;the LH were(16.30±3.18)and(26.61±2.95)m U·mL^(-1),respectively;the E2 were(65.07±3.20)and(45.42±6.80)pg·mL^(-1),respectively.Compared treatment group with control group,the difference of the above indicators was statistically significant(all P<0.05).The incidence of adverse reactions in the treatment group and control group during treatment were 11.76%(4 cases/34 cases)and 9.38%(3 cases/32 cases),the difference was not statistically significant(P>0.05).Conclusion Zhibai Dihuang Pills combined with Kuntai Capsules have a good clinical effect in the treatment of low ovarian reserve,and at the same time,it can promote the recovery of ovarian function and improve hormone levels in patients,can improve the quality of life,with high safety.
作者
卢君
何玉婷
LU Jun;HE Yu-ting(Department of Traditional Chinese Medicine,Ganzhou Maternal and Child Health Hospital,Ganzhou 341000,Jiangxi Province,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2022年第20期2401-2405,共5页
The Chinese Journal of Clinical Pharmacology
关键词
坤泰胶囊
知柏地黄丸
卵巢储备功能
促卵泡激素
雌二醇
Kuntai capsule
Zhibai Dihuang pill
ovarian reserve
follicle stimulating hormone
estradiol
